Sun Pharmaceutical Industries Limited has entered into an in licensing agreement for India and other low-and middle-income countries (LMICs) with MSD for Molnupiravir, an investigational oral antiviral agent currently being studied in a Phase 3 trial for the treatment of non- hospitalized patients with confirmed COVID-19. This agreement would help to accelerate availability of Molnupiravir in India and in other (LMICs post receipt of approvals or emergency authorization by local regulatory agencies.